Allergy Therapeutics PLC
LSE:AGY

Watchlist Manager
Allergy Therapeutics PLC Logo
Allergy Therapeutics PLC
LSE:AGY
Watchlist
Price: 6.25 GBX -0.79% Market Closed
Market Cap: 297.9m GBX
Have any thoughts about
Allergy Therapeutics PLC?
Write Note

Allergy Therapeutics PLC
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Allergy Therapeutics PLC
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Allergy Therapeutics PLC
LSE:AGY
Cash from Financing Activities
ÂŁ34.1m
CAGR 3-Years
N/A
CAGR 5-Years
29%
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Cash from Financing Activities
-ÂŁ8B
CAGR 3-Years
7%
CAGR 5-Years
-30%
CAGR 10-Years
-2%
AstraZeneca PLC
LSE:AZN
Cash from Financing Activities
-$2.2B
CAGR 3-Years
N/A
CAGR 5-Years
-29%
CAGR 10-Years
4%
Verona Pharma PLC
NASDAQ:VRNA
Cash from Financing Activities
$180.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Cash from Financing Activities
-$291m
CAGR 3-Years
-15%
CAGR 5-Years
-5%
CAGR 10-Years
-10%
Dechra Pharmaceuticals PLC
LSE:DPH
Cash from Financing Activities
ÂŁ316.5m
CAGR 3-Years
39%
CAGR 5-Years
10%
CAGR 10-Years
N/A
No Stocks Found

Allergy Therapeutics PLC
Glance View

Market Cap
297.9m GBX
Industry
Pharmaceuticals

Allergy Therapeutics Plc is a biotechnology company. The company is headquartered in Worthing, West Sussex and currently employs 601 full-time employees. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines. Its segments include Central Europe, which include segments, such as Germany, Austria, Switzerland and the Netherlands; Southern Europe, which includes Italy, Spain and Other; the United Kingdom, and Rest of World. The company sells both injectable and sublingual allergen-specific immunotherapies. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL and Peanut SCIT. Its vaccine candidates outside allergy include disease areas, including cancer, asthma, atopic dermatitis and psoriasis. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Venomil, VLP Peanut and ImmunoBON.

AGY Intrinsic Value
4.33 GBX
Overvaluation 31%
Intrinsic Value
Price

See Also

What is Allergy Therapeutics PLC's Cash from Financing Activities?
Cash from Financing Activities
34.1m GBP

Based on the financial report for Dec 31, 2023, Allergy Therapeutics PLC's Cash from Financing Activities amounts to 34.1m GBP.

What is Allergy Therapeutics PLC's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
29%

Over the last year, the Cash from Financing Activities growth was 854%.

Back to Top